Cardiac Toxicity on NSABP B-31

Slides:



Advertisements
Similar presentations
CARDIOVASCULAR EFFECTS OF ANTHRACYCLINE-LIKE CHEMOTHERAPY AGENTS JOHN N. HAMATY FACC, FACOI.
Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results
Purpose To determine whether metoprolol controlled/extended release
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
BCIRG006 - Randomized Phase III Trial Comparing AC-T vs AC-TH vs TCH in HER2 Positive Node Positive or High Risk Node Negative Breast Cancer Initial efficacy.
Heart disease. Congenital Ischemic Hypertensive Valvular Cardiomyopathy Pericardium Tumors.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
HER2-Targeted Therapy THE PROBLEM WITH ‘OFF TARGET’ TOXICITY TO THE HEART Melinda Telli, MD Instructor in Medicine Stanford University 9/12/2008.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
A randomized three-arm multi-centre comparison of: 1 year Herceptin®1 year Herceptin® 2 years Herceptin®2 years Herceptin® or no Herceptin®or no Herceptin®
NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer?
Highlights in the Management of Breast Cancer Rome, May 25-26, 2007 CLINICAL CASE Dott.ssa Simona Gildetti Cattedra di Oncologia Medica Università “G.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Herceptin ® adjuvant therapy: “a triumphal narrative of translational research” Brian Leyland-Jones McGill University Department of Oncology Montreal,
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.
Heart disease. Congenital Ischemic Hypertensive Valvular Cardiomyopathy Pericardium Tumors.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
Adjuvant therapy of HER2 positive early breast cancer The Evidences Antonio Frassoldati Oncologia Clinica - Ferrara.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC  Paclitaxel with Trastuzumab.
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis.
Longer-Term Assessment of Trastuzumab- Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial Marion Procter, Thomas M. Suter, Evandro de.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Malignancy related cardiotoxicity. Cytotoxic drugs  Formation of free oxygen radicals  Induction of immunogenic reactions  Influence of the cytotoxic.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Slamon D et al. SABCS 2009;Abstract 62.
B-31/N9831 First Interim Joint Analysis
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Update on the Watchman Device CRT 2010 Washington, DC
CCO Independent Conference Highlights
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Current Patterns of Care in Breast Cancer: Use of Adjuvant Trastuzumab
Gajria D et al. Proc SABCS 2010;Abstract P
Perez EA et al. SABCS 2009;Abstract 80.
Definitive Analysis of the Primary Outcomes
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
University of Pennsylvania
ASCO 2002 Advances in the Adjuvant Chemotherapy of Breast Cancer
Figure 1. Adjuvant trastuzumab study designs
HOPE: Heart Outcomes Prevention Evaluation study
Nordic sites Sweden Uppsala University Hospital
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
Swain SM et al. Proc SABCS 2012;Abstract P
European Cooperative Trial in Operable Breast Cancer(ECTO): Improved freedom from progression from adding paclitaxel(T) to doxorubicin(A) followed by CMF.
Maya Guglin, MD, PhD University of Kentucky, Lexington, KY
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
Systolic Blood Pressure Intervention Trial (SPRINT)
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Barrios C et al. SABCS 2009;Abstract 46.
Joerg Herrmann, MD, Amir Lerman, MD, Nicole P
Krop I et al. SABCS 2009;Abstract 5090.
Jones SE et al. SABCS 2009;Abstract 5082.
Untch M et al. Proc SABCS 2010;Abstract P
Global Registry of Acute Coronary Events: GRACE
and the NSABP Investigators
Javier Escaned et al. JCIN 2018;11:
Presentation transcript:

Cardiac Toxicity on NSABP B-31 Charles E. Geyer, Jr. MD Director of Medical Affairs NSABP Pittsburgh, PA September 17, 2005

B-31 Cardiac Monitoring Program Development Group John Bryant, PhD Edward Romond, MD Elizabeth Tan-Chiu, MD Sandra Swain, MD

B-31 Cardiac Monitoring Program Data Management Priya Rastogi, MD Greg Yothers, PhD Ann Brown, ScD Cheryl Butch, RN, BA Carole Donnelly Steve Zieger

Operable Breast Cancer Path Positive Axillary Nodes NSABP B-31 Operable Breast Cancer HER-2 Positive Tumor Path Positive Axillary Nodes Randomization AC q3wk x 4 Paclitaxel q3wk x 4* or Paclitaxel qwk x 12* AC q3wk x 4 Paclitaxel q3wk x 4* or Paclitaxel qwk x 12* + Trastuzumab qwk x 52 * Choice of Taxol schedule and hormonal therapy at discretion of investigator – stratification factors

B-31 Design Assumptions A potential 4% incidence of CHF was anticipated with concurrent trastuzumab and paclitaxel following AC This would be acceptable if ≥25% relative risk reduction for death were demonstrated, particularly if cardiac effects were largely reversible 10 year OS improvement projection 62-70%

B-31 Cardiac Eligibility Criteria Normal left ventricular ejection fraction No past or active cardiac disease including: History of myocardial infarction History of congestive heart failure Angina pectoris requiring medication Arrhythmia requiring medication Clinically significant valvular disease Uncontrolled hypertension Left ventricular hypertrophy Cardiomegaly on CXR

B-31 LVEF Evaluation Schedule Arm 1 AC x 4 Paclitaxel mo. 3 mos. 6 mos. 9 mos. 18 mos. Arm 2 AC x 4 Trastuzumab + Paclitaxel mo. 3 mos. 6 mos. 9 mos. 18 mos.

NSABP B-31 Criteria for Trastuzumab Initiation Trastuzumab only initiated if Patient remained free of cardiac symptoms AND Post AC LVEF ≥ LLN AND Absolute decline was ≤ 15 percentage points from pre-entry value Patients not meeting post AC criteria Trastuzumab arm - 66/974 (6.8%) Control arm - 82/962 (8.5%) Combined arms - 148/1936 (7.6%)

B-31 Cardiac Event Primary Endpoint for Cardiac Safety If either of the following occurred Definite or probable Cardiac Death Symptomatic CHF confirmed by MUGA or Echo Dyspnea with normal activity or at rest AND Documented absolute drops in LVEF of: Greater than 10% to below 55%, or Greater than 5% to below institution’s LLN Absolute difference of ≤ 4% in CE between arms in patients with good post AC LVEFs considered acceptable .

Symptomatic Patients Real Time Blinded Evaluation Symptoms of possible CHF reported within 14 days regardless of severity (Form CR) Source documents blinded centrally in regards to trastuzumab therapy Reviewed by each member of external Cardiac Advisory Panel (CAP) Majority determination of whether or not protocol criteria for a Cardiac Event were met

NSABP B-31 Cardiac Event Rates Romond et al. ASCO 2005

Trastuzumab Associated CHF Risk Factors 9/48 3 Year cumulative incidence of CHF: Arm 2 evaluable cohort 3-Yr Cum Inc of CHF (%) 20.0% 3/48 11/196 1/160 2/160 6.8% 5/229 6.1% 2.5% 1.1% 1.5 % Age ≤49 ≥50 ≤49 ≥50 ≤49 ≥50 Post AC 50-54 55-64 65+ LVEF

Recovery of Patients Reporting Symptoms of Possible CHF ACPTX AC PTX+H Confirmed CHF (n) 4 31 Followed ≥ 6 months from CHF 1 27 Symptoms during last 6 months 1/1 1/27 On meds during last 6 months 1/1 18/27 Not confirmed with CHF (n) 8 43 Followed ≥ 6 months from symptoms 6 39 Symptoms during last 6 months 0/6 1/39 On meds during last 6 months 0/6 8/39

Histograms of Left Ventricular Ejection Fraction Arm 2 patients with symptoms meeting criteria for CHF (a) (N=30) (N=25) (b) Arm 2 patients with symptoms not meeting criteria for CHF (N=35) (c) (N=44) (d) Proportion Arm 2 patients discontinuing H due to asymptomatic decline in LVEF (e) (N=80) (f) (N=56) < 30 70+ < 30 70+ 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 Nadir LVEF Current LVEF, 18+ Months

B-31 LVEF Evaluation Schedule Arm 1 AC x 4 Paclitaxel mo. 3 mos. 6 mos. 9 mos. 18 mos. Arm 2 AC x 4 Trastuzumab + Paclitaxel mo. 3 mos. 6 mos. 9 mos. 18 mos.

Asymptomatic Patients Criteria for Continuing Trastuzumab Absolute Decrease of < 10% Absolute Decrease of 10 - 15% Absolute Decrease of  15% Relationship of 6 and 9 mo. LVEF to LLN Within Normal Limits 1- 5% below LLN  6% below LLN Cont. Cont.* Cont. Hold * Hold * Once the patients start Herceptin, they will be monitored at set intervals by MUGA scan. The above criteria must be followed for continuing or stopping Herceptin in patients who are asymptomatic. If a repeat MUGA scan is indicated, that MUGA scan must fall into one of the categories labeled “continue” (above) before the patient can proceed with further weekly Herceptin doses. * Repeat LVEF assessment after 4 weeks - If criteria for continuation met – resume trastuzumab - If 2 consecutive holds, or total of 3 holds occur – discontinue trastuzumab

NSABP B-31 Trastuzumab Discontinuation Due to Asymptomatic or Symptomatic Cardiac Dysfunction by Quarter